338 Results from a phase 1 study of ARQ 092, a novel pan AKT-inhibitor, in subjects with advanced solid tumors or recurrent malignant lymphoma. (September 2015) - Tolcher, A.; Harb, W.; Sachdev, J.; Papadopoulos, K.; Bordoni, R.; Chai, F.; Larmar, M.; Savage, R.; Abbadessa, G.; Saleh, M.